Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma Inc News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (3 days ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (4 days ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (4 days ago) • Edgar (US Regulatory)

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Thursday 14 November 2024 (4 days ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Wednesday 13 November 2024 (6 days ago) • Edgar (US Regulatory)

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Tuesday 5 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Friday 1 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Friday 11 October 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Saturday 21 September 2024 (2 months ago) • Edgar (US Regulatory)

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Saturday 21 September 2024 (2 months ago) • GlobeNewswire Inc.

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Saturday 14 September 2024 (2 months ago) • GlobeNewswire Inc.

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Wednesday 11 September 2024 (2 months ago) • GlobeNewswire Inc.

More Sutro Biopharma Inc News Articles

Round Hill Music Royalty

iPath S&P VEQTOR ETN

Context Therapeutics

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions